Jourik A. Gietema

89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer

Frederike Bensch, Elly L. van der Veen, Marjolijn N. Lub–de Hooge et al. · Nature Medicine · 2018 · 734 citations · Full text

Medicine, Oncology, Pharmacology +17

Validation and Modification of a Prediction Model for Acute Cardiac Events in Patients With Breast Cancer Treated With Radiotherapy Based on Three-Dimensional Dose Distributions to Cardiac Substructures

Veerle A.B. van den Bogaard, Bastiaan D.P. Ta, A. van der Schaaf et al. · Journal of Clinical Oncology · 2017 · 503 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial

Michiel S. van der Heijden, Matthew D. Galsky, Yohann Loriot et al. · The Lancet Oncology · 2020 · 498 citations · Full text

Medicine, Oncology, Pharmacology +14

Cardiovascular Morbidity in Long-Term Survivors of Metastatic Testicular Cancer

M.T. Meinardi, Jourik A. Gietema, W. T. A. van der Graaf et al. · Journal of Clinical Oncology · 2000 · 491 citations

Medicine, Cardiology, Oncology +14

Treatment-Specific Risks of Second Malignancies and Cardiovascular Disease in 5-Year Survivors of Testicular Cancer

Alexandra W. van den Belt‐Dusebout, Ronald de Wit, Jourik A. Gietema et al. · Journal of Clinical Oncology · 2007 · 459 citations · Full text

Medicine, Oncology, Radiation Oncology +17